Scott Lowenstein

Scott Lowenstein currently oversees early-stage product development for The New York Times' Research & Development team, focusing on cryptography for media provenance, 3D and spatial content, and machine learning applications. They previously served as a Director at Global Strategy Group, managing public opinion research, and co-founded a telemedicine company, Crux Health, which was accepted into Y Combinator. Scott has also held various roles at The New York Times, including Research & Development Strategist, where they explored the application of emerging technologies in journalism. They earned an MBA from Stanford University Graduate School of Business and are currently pursuing a BA in Applied Mathematics-Economics at Brown University.